Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

Reviewing the Role of SGLT2 Inhibitors in Heart Failure

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    With the prevalence of heart failure continuing to rise worldwide, recent trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors may improve impairments and decrease the risk of hospitalizations. So based on these recent findings, what exactly is their role in the management of patients with heart failure? Find out with Dr. Javed Butler as he speaks with Dr. Mikhail Kosiborod, Professor of Medicine at the University of Missouri-Kansas City and Vice-President of Research at Saint Luke's Health System.

Recommended
Details
Presenters
Comments
  • Overview

    With the prevalence of heart failure continuing to rise worldwide, recent trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors may improve impairments and decrease the risk of hospitalizations. So based on these recent findings, what exactly is their role in the management of patients with heart failure? Find out with Dr. Javed Butler as he speaks with Dr. Mikhail Kosiborod, Professor of Medicine at the University of Missouri-Kansas City and Vice-President of Research at Saint Luke's Health System.

Schedule15 Oct 2024